- In August 2022, ICPA Health Products Ltd, an India-based leader in oral healthcare, announced the launch of its Trioplast anti-ulcer dental paste. Formulated with triamcinolone acetonide as the key active ingredient, this paste effectively reduces mouth swelling and irritation by modulating the body’s response to allergens. The introduction of Trioplast enhances ICPA's product line, offering an effective solution for individuals suffering from mouth ulcers and providing relief from related discomfort
- In September 2022, Mucocort AB, a Swedish company, launched a groundbreaking self-absorbing pain relief patch specifically aimed at individuals suffering from recurrent mouth ulcers, or aphthous stomatitis. This innovative product offers targeted pain relief, providing a convenient and effective solution for managing the discomfort associated with mouth ulcers. By addressing a common yet often untreated condition, Mucocort's new patch enhances the company's product offering and responds to the growing demand for advanced, user-friendly treatments
- In September 2022, Dow University of Health Sciences sponsored a clinical trial titled "Therapeutic Effect of Folic Acid in Healing of Oral Ulcers," designed to assess the effectiveness of topical folic acid in promoting the healing of oral ulcerations. The trial aimed to evaluate the potential therapeutic benefits of folic acid in accelerating recovery and reducing symptoms associated with mouth ulcers. This research contributes to the growing interest in non-invasive, topical treatments for oral ulcers, highlighting the potential for folic acid as a viable treatment option
- In September 2022, Mucocort AB, a Swedish company, introduced a distinctive self-absorbing pain relief patch designed specifically for individuals experiencing recurrent mouth ulcers, commonly known as aphthous stomatitis. This innovative patch offers targeted pain relief, providing a convenient and effective solution for managing the discomfort associated with mouth ulcers. Mucocort's development responds to the growing demand for advanced, non-invasive treatments for recurrent oral conditions, improving the overall patient experience
- In December 2021, Forward Science introduced BioStom, a non-opioid oral pain-relief gel designed to alleviate pain caused by oral wounds, mouth sores, and mucosal ulcers. This innovative product not only expanded the company's portfolio but also addressed the increasing demand for opioid-free pain management solutions. By offering a safer alternative for oral pain relief, BioStom aligned with broader healthcare trends prioritizing non-opioid treatments, enhancing Forward Science's position in the market
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Minor, Major, and Herpetiform), Indication Type (Aphthous Stomatitis, Oral Lichen Planus, and Others), Drug Class (Corticosteroids, Analgesics, Antibiotics, Anti-Inflammatory Agents, and Others), Formulation Type (Sprays, Mouthwash, Gels, Lozenges, and Others), Route of Administration (Oral and Topical), End-Users (Homecare, Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Mouth Ulcers Treatment Market size was valued at USD 1.64 USD Billion in 2024.
The Global Mouth Ulcers Treatment Market is projected to grow at a CAGR of 3.95% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
